, Volume 20, Issue 3–4, pp 639–654 | Cite as

Metals ions and neurodegeneration

  • Francisco Molina-Holgado
  • Robert C. Hider
  • Alessandra Gaeta
  • Robert Williams
  • Paul Francis


Neurodegenerative disorders include a variety of pathological conditions, which share similar critical metabolic processes such as protein aggregation and oxidative stress, both of which are associated with the involvement of metal ions. In this review Alzheimer’s disease and Parkinson’s disease are mainly discussed, with the aim of identifying common trends underlying these neurological conditions. Chelation therapy could be a valuable therapeutic approach, since metals are considered to be a pharmacological target for the rationale design of new therapeutic agents directed towards the treatment of neurodegeneration.


Neurodegeneration Protein aggregation Oxidative stress Aβ-amyloid α-Synuclein Chelation therapy Iron 



Alzheimer’s disease




Amyloid precursor protein


Blood brain barrier


Central nervous system






Ethylenediaminetetraacetic acid




Iron-responsive element


Parkinson’s disease


Prion protein


Normal isoform of the prion protein


Scrapie isoform of the prion protein


Reactive oxygen species


Substantia nigra


Substantia nigra pars compacta


Superoxide dismutase


Tumour necrosis factor


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abeysinghe RD, Roberts PJ, Cooper, CE, Maclean KH, Hider RC, Porter JB (1996) The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J Biol Chem 271:7965–7972PubMedCrossRefGoogle Scholar
  2. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain of Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329PubMedCrossRefGoogle Scholar
  3. Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury. Phil Trans R Soc Lond B Biol Sci 358:1669–1677CrossRefGoogle Scholar
  4. Allan SM, Tyrrell PJ, Rothwell NJ (2005) Interleukin-1 and neuronal injury. Nat Rev Immunol 5:629–640PubMedCrossRefGoogle Scholar
  5. Antzutkin ON, Leapman RD, Balbach JJ, Tycko R (2002) Sopramolecular structural constraints on Alzheimer’s β-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry 41:15436–15450PubMedCrossRefGoogle Scholar
  6. Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, Martins RN (2003) Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Rev 43:1–16PubMedCrossRefGoogle Scholar
  7. Beard JL, Wiesinger JA, Connor JR (2003) Pre- and postweaning iron deficiency alters myelination in Sprague–Dawley rats. Dev Neurosci 25:308–315PubMedCrossRefGoogle Scholar
  8. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin-proteosome system by protein aggregation. Science 292:1552–1555PubMedCrossRefGoogle Scholar
  9. Ben-Shacar D, Kahana N, Kampel V, Warshawsky A, Youdim MBH (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46:254–263CrossRefGoogle Scholar
  10. Bonilla E (2000) Huntington disease. A review. J Clin Invest 41:117–141Google Scholar
  11. Brion S, Mirol J, Psimaras A (1973) Recent findings in Pick’s disease. In: Zimmerman HM (eds) Progress in neuropathology, vol 2. Grune and Stratton, New York, pp 421–452Google Scholar
  12. Brown DR (2001) Copper and prion disease. Br Res Bull 55:165–173CrossRefGoogle Scholar
  13. Brunk UT, Jones CB, Sohal RS (1992) A novel hypothesis of lipofuscinogenesis and cellular aging based on interactions between oxidative stress and autophagocytosis. Mut Res 275:395–403Google Scholar
  14. Brunk UT, Terman A (2002) Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Rad Biol Med 33:611–619PubMedCrossRefGoogle Scholar
  15. Bucciantini M, Giannoni F, Chiti F et al (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:501–511CrossRefGoogle Scholar
  16. Bush AI, Huang X, Fairlie DP (1999) The possible origin of free radicals from amyloid β-peptides in Alzheimer’s disease. Neurobiol Ageing 20:335–337CrossRefGoogle Scholar
  17. Bush AI (2002) Metal complexing agents as therapies for Alzheimer’s disease. Neurobiol Ageing 23:1031–1038CrossRefGoogle Scholar
  18. Butterfield DA, Kanski J (2001). Brain oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122:945–962PubMedCrossRefGoogle Scholar
  19. Cherny RA, Barnham KJ, Lynch T et al (2000). Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer’s disease. J Struct Biol 130:209–216PubMedCrossRefGoogle Scholar
  20. Cherny RA, Atwood CS, Xilinas ME et al (2001) Treatment with a copper–zinc chelator markedly and rapidly inhibits b-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:665–676PubMedCrossRefGoogle Scholar
  21. Chetley A, Gilbert D (1986) Health action international. International Organisation of Consumers Unions, The HangueGoogle Scholar
  22. Claesen ME, Clements ML (1989) Ridding the world of hydroxyquinolines. Br Med J 299:527–528CrossRefGoogle Scholar
  23. Cohen AS, Shirahama T, Skinner M (1982) Electron microscopy of amyloid. In: Harris JR (eds) Electron microscopy of proteins, vol 3. Academic Press, London UK, pp 165–205Google Scholar
  24. Cohen FE (1999) Protein misfolding and prion diseases. J Mol Biol 293:313–320PubMedCrossRefGoogle Scholar
  25. Connor JR, Snyder BS, Arosio P, Loeffler DA, Lewitt P (1995) A quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer’s diseased brains. J Neurochem 65:717–724PubMedCrossRefGoogle Scholar
  26. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291–20299PubMedCrossRefGoogle Scholar
  27. Crapper Mclachlan DR, Dalton AJ, Kruck TPA et al (1991) Effect of desferrioxamine on the clinical progress of Alzheimer’s disease. Lancet 337:1304–1308PubMedCrossRefGoogle Scholar
  28. Crossthwaite AJ, Williams RJ (2002) Hydrogen peroxide-mediated phosphorilation of ERK1/2, Akt/PKB and JNK in cortical neurons: dependence on Ca2+ and PI 3-kinase. J Neurochem 80:24–36PubMedCrossRefGoogle Scholar
  29. Dexter DT, Wells FR, Lees AJ (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:381–389PubMedCrossRefGoogle Scholar
  30. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285–298PubMedCrossRefGoogle Scholar
  31. Di Patti MC, Persichini T, Mazzone V, Polticelli F, Colasanti M, Musci G (2004) Interleukin-1 beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferroportin-1 synthesis. Neurosci Lett 363:182–186PubMedCrossRefGoogle Scholar
  32. Dobson MC (2003a) Protein folding and disease: a view from the first horizon symposium. Nat Drug Disc 2:154–160CrossRefGoogle Scholar
  33. Dobson MC (2003b) Protein folding and misfolding. Nature 426:884–890CrossRefGoogle Scholar
  34. Duffy PE, Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and Locus caeruleus in Parkinson’s disease. J Neuropathol Exp Neurol 24:398–414CrossRefGoogle Scholar
  35. Floyd RA (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236–245PubMedCrossRefGoogle Scholar
  36. Floyd RA, Hensley K (2002) Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23:795–807PubMedCrossRefGoogle Scholar
  37. Gaeta A, Hider RC (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146:1041–159PubMedCrossRefGoogle Scholar
  38. Gotz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: Free radical production in neural degeneration. Pharmacol Ther 63:37–122PubMedCrossRefGoogle Scholar
  39. Grunblatt E, Mandel S, Youdim MB (2000) MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies. J Neurol 247(Suppl 2):95–102Google Scholar
  40. Habgood MD, Liu ZD, Dehkordi LS, Khodr HH, Abbott J, Hider RC (1999) Investigation into the correlation between the structure of hydroxypyridinones and blood–brain barrier permeability. Biochem Pharmacol 57:1305–1310PubMedCrossRefGoogle Scholar
  41. Halliwell B (1992) Reactive oxygen species the central nervous system. J Neurochem 59:1609–1623PubMedCrossRefGoogle Scholar
  42. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356PubMedCrossRefGoogle Scholar
  43. Harris DC, Aisen P (1973) Facilitation of Fe(II) autoxidation by Fe(III) complexing agents. Biochim Biophys Acta 329:156–158PubMedGoogle Scholar
  44. Hartley DM, Walsh DM, Ye CP et al (1999) Protofibrillar intermediates of amyloid b-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurones. J Neurosci 19(20):8876–8884PubMedGoogle Scholar
  45. Hedge ML, Jagannatha Rao KS (2003) Challenges and complexities of α-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson’s disease. Arch Biochem Biophys 418:169–178CrossRefGoogle Scholar
  46. Hider RC, Hall AD (1991) Clinically useful chelators of tripositive elements. Prog Med Chem 28:41–173PubMedCrossRefGoogle Scholar
  47. Hider RC (1995) Potential protection from toxicity by oral iron chelators. Toxicol Lett 82–83:961–967PubMedCrossRefGoogle Scholar
  48. Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T, Gabizon R (2003) Copper binding to PrPC may inhibit prion disease propagation. Br Res 993:192–200CrossRefGoogle Scholar
  49. Hirsh EC, Brandel J-P, Galle P (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson’s disease: an X-ray microanalysis. J Neurochem 56:446–451CrossRefGoogle Scholar
  50. Holander D, Ricketts D, Boyd CAR (1988) Importance of probe molecular geometry in determining intestinal permeability. Can J Gastroenterol 2:35A–38AGoogle Scholar
  51. Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274:99–102PubMedCrossRefGoogle Scholar
  52. Huang X, Atwood CS, Hartshorn MA et al (1999) The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38:7609–7616PubMedCrossRefGoogle Scholar
  53. Jeffrey M, Goodsir CM, Bruce ME, Mcbride PA, Scott JR (1994) Infection-specific prion protein (PrP) accumulates on neuronal plasmalemma in scrapie-infected mice. Ann NY Acad Sci 724:327–330PubMedCrossRefGoogle Scholar
  54. Jelliger KA (1999) The role of iron in neurodegeneration: prospects for pharmacology of Parkinson’s disease. Drugs Aging 14:115–140CrossRefGoogle Scholar
  55. Kaur D, Yantiri F, Rajagopalan S et al (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37:899–909PubMedCrossRefGoogle Scholar
  56. Kamenetz F, Tomita T, Hsieh H et al (2003) APP processing and synaptic function. Neuron 37:925–937PubMedCrossRefGoogle Scholar
  57. Klein WL, Krafft GA, Finch CE (2001) Targeting small Aβ oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24:219–224PubMedCrossRefGoogle Scholar
  58. Laine J, Marc M-E, Sy M-S, Axelrad H (2001) Cellular and subcellular morphological localization of normal prion protein in rodent cerebellum. Eur J Neurosci 14:47–56PubMedCrossRefGoogle Scholar
  59. Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Aβ 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453PubMedCrossRefGoogle Scholar
  60. Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104:469–481PubMedCrossRefGoogle Scholar
  61. Lee J-Y, Friedman JE, Angel I, Kozak A, Kohj JY (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice. Neurobiol aging 25:1315–1321PubMedCrossRefGoogle Scholar
  62. Levine SM, Chakrabarty A (2004) The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 1012:252–266PubMedCrossRefGoogle Scholar
  63. Liu ZD, Lockwood M, Rose S, Theobald AE, Hider RC (2001) Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase. Biochem Pharmacol 61:285–290PubMedCrossRefGoogle Scholar
  64. Liu ZD, Hider RC (2002a) Design of clinically useful iron(III)-selective chelators. Med Res Rev 22:26–64CrossRefGoogle Scholar
  65. Liu ZD, Hider RC (2002b). Design of iron chelators with therapeutic application. Coord Chem Rev 232:151–171CrossRefGoogle Scholar
  66. Liu ZD, Kayyali R, Hider RC, Porter JB, Theobald AE (2002) Design, synthesis, and evaluation of novel 2-substitued 3-hydroxypyridin-4-ones: structure-activity investigation of metalloenzyme inhibition by iron chelators. J Med Chem 45:631–639Google Scholar
  67. Lovell MA, Robertson JD, Teesdal WJ, Campbell JL, Markesbery WR (1998). Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158:47–52PubMedCrossRefGoogle Scholar
  68. Lozoff B, Beard J, Connor J, Barbara F, Georgieff M, Schallert T (2006) Long-lasting neural and behavioural effects of iron deficiency in infancy. Nutr Rev 64:S34–43PubMedCrossRefGoogle Scholar
  69. Lue LF, Kuo Y-M, Roher AE et al (1999) Soluble amyloid β-peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155:853–862PubMedGoogle Scholar
  70. Maguire-Zeiss KA, Short DW, Federoff HJ (2005) Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson’s disease? Brain Res Mol Brain 134(1):18–23CrossRefGoogle Scholar
  71. Mandel S, Weinreb O, Amit T, Youdim MB (2005) Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48:379–387PubMedCrossRefGoogle Scholar
  72. Martell AE, Smith RM (1974–1989) Critical stability constant, vol 1–6. Plenum Press, LondonGoogle Scholar
  73. Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS (1986). Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin Sci 71:71–80PubMedGoogle Scholar
  74. Mc Lean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46:860–866CrossRefGoogle Scholar
  75. Merz PA, Sommerville RA, Wisniewsky HM, Ikbal K (1981). Abnormal fibrils from scrapie-infected brain. Acta Neuropathol 54:63–74 (Berlin)PubMedCrossRefGoogle Scholar
  76. Miranda S, Opazo C, Larrondo LF et al (2000) The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer’s disease. Prog. Neurobiol. 62:633–648PubMedCrossRefGoogle Scholar
  77. Mizuno Y, Ohta S, Tanaka M et al (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun 163:1450–1455PubMedCrossRefGoogle Scholar
  78. Molina-Holgado F, Williams RJ, Gaeta A et al (2006) Neuroprotective actions of an iron chelator against Alzheimer’s disease-relevant insults. Poster session, 10th international conference on Alzheimer’s disease and related disorders’s, Madrid, SpainGoogle Scholar
  79. Oakley GP (1973) The neurotoxicity of the halogenated hydroxyquinolines. JAMA 225(4):395–397PubMedCrossRefGoogle Scholar
  80. O’Brien-Ladner AR, Nelson SR, Murphy WJ, Blumer BM, Wesselius LJ (2000) Iron is a regulatory component of human IL-1beta production. Support for regional variability in the lung. Am J Respir Cell Mol Biol 23:112–119PubMedGoogle Scholar
  81. Olanow CW (1992) Magnetic resonance imaging in parkinsonism. Neurol Clin North Am 405–420Google Scholar
  82. Olanow CW, Youdim MB (1996) Neurodegeneration and neuroprotection in Parkinson’s disease. Academic Press, pp 55–59Google Scholar
  83. Oldendorf WH (1974) Lipid solubility and drug penetration of the blood–brain barrier. Proc Soc Exp Biol Med 147:813–816PubMedGoogle Scholar
  84. Olivieri N, Koren G, Hermann C et al (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336:1275–1279PubMedCrossRefGoogle Scholar
  85. Paik SR, Shin H-J, Lee J-H, Chang C-S, Kim J (1999) Copper(II)-induced self-oligomerisation of α-synuclein. Biochem J 340:821–828PubMedCrossRefGoogle Scholar
  86. Palm A (1932) Untersuchung in des chinolin reihe. Arch Exp Pathol Pharmacol 199:176–185CrossRefGoogle Scholar
  87. Pan K, Baldwin M, Nguyen J et al (1993) Conversion of α-helices β-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 90:10962–10966PubMedCrossRefGoogle Scholar
  88. Prusiner SB, Mckinley MP, Bowman KA et al (1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349–358PubMedCrossRefGoogle Scholar
  89. Prusiner SB (1991) Molecular biology of prion disease. Science 252:1515–1522PubMedCrossRefGoogle Scholar
  90. Prusiner SB (2001) Neurodegenerative diseases and prions. N Engl J Med 344:1516–1526PubMedCrossRefGoogle Scholar
  91. Raymond KN, Müller G, Matzanke BF (1984) Complexation of iron by siderophores: a review of their solution and structural chemistry and biological function. Top Curr Chem 58:49–102Google Scholar
  92. Riederer P, Sofic E, Rausch WD, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J Neurochem 52:515–520PubMedCrossRefGoogle Scholar
  93. Rochet JC, Lansbury PT (2000) Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 10:60–80PubMedCrossRefGoogle Scholar
  94. Roher AE, Chaney MO, Kuo Y-M et al (1996) Morphology and toxicity of Aβ-(1–12) dimmer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem 271:20631–20635PubMedCrossRefGoogle Scholar
  95. Rogers JT, Lahiri DK (2004) Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets 5:535–551PubMedCrossRefGoogle Scholar
  96. Rogers JT, Leiter LM, Mcphee J et al (1999) Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by Interleukin-1 through 5’-untranslated region sequences. J Biol Chem 274:6421–6431Google Scholar
  97. Rogers JT, Randall JD, Cahill CM et al (2002) An iron-responsive element type II in the 5’-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 277:45518–45528PubMedCrossRefGoogle Scholar
  98. Rose FC, Gawel M (1984) Clioquinol neurotoxicity: an overview. Acta Neurol Scand 80(Suppl 100):137–145Google Scholar
  99. Saggu H, Cooksey J, Dexter D (1989) A selective increase in a particular superoxide dismutase activity in Parkinsonian substantia nigra. J Neurochem 53:692–697PubMedCrossRefGoogle Scholar
  100. Sanchez-Ramos J, Overvick E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2’-deoxy-guanoxine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3:197–204Google Scholar
  101. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA (2000) Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross β-conformation. Proc Natl Acad Sci USA 97:4897–4902PubMedCrossRefGoogle Scholar
  102. Shastry BS (2003) Neurodegenerative disorders of protein aggregation. Neurochem Int 43:1–7PubMedCrossRefGoogle Scholar
  103. Sherki YG, Melamed E, Offen D (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40:959–975CrossRefGoogle Scholar
  104. Shin R-W, Kruck TPA, Murayama H, Kitamoto T (2003) A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease. Br Res 961:139–146CrossRefGoogle Scholar
  105. Sikorski P, Atkins EDT, Serpell LC (2003) Structure and texture of fibrous crystals formed by Alzheimer’s Aβ (11–15) peptide fragment. Structure 11:915–926PubMedCrossRefGoogle Scholar
  106. Sofic E, Riederer P, Heinsen H (1988) Increased Iron(Iii) and total iron content in post mortem, substantia nigra of parkinsonian brain. J Neural Trans 74:199–205CrossRefGoogle Scholar
  107. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130PubMedCrossRefGoogle Scholar
  108. Stahl N, Borchelt DR, Hsiao K, Prusiner SB (1987) Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51:229–240PubMedCrossRefGoogle Scholar
  109. Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedCrossRefGoogle Scholar
  110. Torok M, Milton S, Kayed R et al (2002) Structural and dynamic features of Alzheimer’s Aβ peptide in amyloid fibrils studied by site-directed spin labelling. J Biol Chem 277:40810–40815PubMedCrossRefGoogle Scholar
  111. Tsubaki T, Honma Y, Hosh M (1971) Neurological syndrome associated with clioquinol. Lancet 1:696–697PubMedCrossRefGoogle Scholar
  112. Tycko R (2004) Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol 14:1–8CrossRefGoogle Scholar
  113. Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation and fibrillation of human α-synuclein. J Biol Chem 276:10737–10744PubMedCrossRefGoogle Scholar
  114. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB (1993) Characterisation of amyloid peptide from human cerebrospinal fluid. J Neurochem 61:1965–1968PubMedCrossRefGoogle Scholar
  115. Walsh DM, Hartley DM, Kusumoto Y et al (1999) Amyloid β protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J Biol Chem 274:25945–25952PubMedCrossRefGoogle Scholar
  116. Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539PubMedCrossRefGoogle Scholar
  117. Wang SS, Becerra-Arteaga A, Good TA (2002) Development of a novel diffusion-based method to estimate the size of the aggregated Aβ species responsible for neurotoxicity. Biotechnol Bioeng 80:50–59PubMedCrossRefGoogle Scholar
  118. Warshawsky B., Youdim MBH, Ben-Shacar D (2000) Pharmaceutical compositions compromising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International Publication number WO 00/74664A2Google Scholar
  119. Wisniewsky HM, Coblentz JM, Terry RD (1972) Pick’s disease. A clinical and ultrastructural study. Arch Neurol 26:97–108Google Scholar
  120. Xu J, Kao S-Y, Lee FJS, Song W, Jin L-W, Yankner BA (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606PubMedCrossRefGoogle Scholar
  121. Ye FQ, Allen PS, Martin WRW (1996) Basal ganglia iron content in Parkinson’s disease measured with magnetic resonance. Mov Disord 11:243–249PubMedCrossRefGoogle Scholar
  122. Yokel RA, Fredenburg AM, Meurer KA, Skinner TL (1995) Influence of lipophilicity on the bioavailability and disposition of orally active 3-hydroxypyridin-4-one metal chelators. Drug Metab Dispos 23:1178–1180PubMedGoogle Scholar
  123. Youdim MB, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson’s disease with iron chelators. Ann NY Acad Sci 890:7–25PubMedCrossRefGoogle Scholar
  124. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett 510:216–220PubMedCrossRefGoogle Scholar
  125. Zhang X, Haaf M, Todorich B et al (2005) Cytokine toxicity to oligodendrocyte precursors is mediated by iron. Glia 52(3):199–208PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Francisco Molina-Holgado
    • 1
  • Robert C. Hider
    • 2
  • Alessandra Gaeta
    • 2
  • Robert Williams
    • 1
  • Paul Francis
    • 1
  1. 1.Wolfson Centre for Age Related DiseasesKing’s CollegeLondonUK
  2. 2.Division of Pharmaceutical ScienceKing’s CollegeLondonUK

Personalised recommendations